0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptic Ulcer Drugs Market by Route Of Administration, Sales Channel, Brand Type, Dosage Form, End User, Distribution Channel, Drug Class - Global Forecast to 2030- Product Image
Peptic Ulcer Drugs Market by Route Of Administration, Sales Channel, Brand Type, Dosage Form, End User, Distribution Channel, Drug Class - Global Forecast to 2030- Product Image
Sale

Peptic Ulcer Drugs Market by Route Of Administration, Sales Channel, Brand Type, Dosage Form, End User, Distribution Channel, Drug Class - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889038
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Peptic Ulcer Drugs Market grew from USD 4.73 billion in 2024 to USD 4.99 billion in 2025. It is expected to continue growing at a CAGR of 5.25%, reaching USD 6.43 billion by 2030.

Understanding the Evolution of Peptic Ulcer Therapeutics

The global approach to peptic ulcer treatment has undergone profound transformation, driven by advances in pharmacology, evolving patient demographics, and heightened regulatory scrutiny. Today’s decision-makers must navigate a landscape shaped by novel molecular entities, shifting prescribing patterns and an increasingly complex payer environment. An effective introduction to this multifaceted arena requires clarity on recent breakthroughs in proton pump inhibitors and H2 receptor antagonists, as well as an appreciation for how clinical practice guidelines have adapted to emerging scientific evidence.

By framing these developments within a broader healthcare context, we can pinpoint critical drivers such as aging populations, the rising prevalence of Helicobacter pylori infections in developing regions and growing patient preference for noninvasive therapy options. This opening discussion lays the foundation for understanding how manufacturers, payers and providers align on efficacy, safety and cost considerations. It also surfaces the imperative for stakeholders to anticipate regulatory shifts and policy reforms that will ultimately dictate how peptic ulcer therapies are accessed, reimbursed and adopted on a global scale.

Revolutionary Shifts Redefining the Peptic Ulcer Drug Sphere

The peptic ulcer drug sphere is experiencing revolutionary realignment as precision medicine, digital health tools and novel regulatory frameworks converge. Purpose-driven formulation innovations-such as extended-release proton pump inhibitors-are redefining treatment adherence, while real-world evidence platforms are accelerating post-market validation. These shifts are not isolated; they herald a new era in patient management that emphasizes personalized dosing, streamlined access and integrated care pathways.

Moreover, the integration of telemedicine and remote monitoring has enabled earlier intervention, reducing the risk of ulcer complications and hospital admissions. Innovative reimbursement models that reward outcomes over volume further incentivize manufacturers to invest in therapies with demonstrable long-term benefits. As we explore these transformative changes, it becomes clear that market incumbents and new entrants alike must cultivate agility to capitalize on emerging opportunities and to navigate a healthcare environment driven by data, patient-centricity and cost containment.

Assessing the Ripple Effects of US Tariffs on Peptic Ulcer Treatments

The imposition of new tariffs by the United States in 2025 has reverberated across the global supply chain for peptic ulcer drugs, prompting manufacturers to reassess sourcing strategies and adjust pricing structures. Raw material costs for key active pharmaceutical ingredients have surged, driving margin pressure for both established producers and generic manufacturers. This external cost shock has triggered a wave of regional production realignment, as companies weigh the benefits of domestic manufacturing against longstanding economies of scale in Asia.

As import duties amplify landed costs, stakeholders have accelerated negotiations with contract manufacturers and explored alternative excipients to preserve product affordability. Payer negotiations have grown more complex, with formulary committees demanding greater transparency on cost breakdowns and supply chain resiliency. In response, forward-thinking organizations are forging strategic alliances with raw material suppliers, investing in vertical integration or establishing buffer inventories to mitigate volatility in tariff exposure.

Unveiling Critical Segmentation Dynamics Driving Market Behavior

A nuanced view of the peptic ulcer market emerges when we examine how different categories interact with patient needs and commercial dynamics. Oral formulations continue to dominate due to convenience and low administration costs, whereas parenteral options remain essential in acute hospital settings or for patients with absorption challenges. The balance between over-the-counter accessibility and prescription oversight shapes patient self-management, with nonprescription alternatives catering to mild symptoms while prescription innovations target refractory cases.

Within the brand spectrum, proprietary compounds leverage advanced delivery technologies to justify premium pricing, while generics drive volume growth by offering affordable alternatives post-patent expiry. Capsules, tablets and injections each answer distinct clinical requirements; immediate-release tablets often serve initial symptom control, whereas capsules with enteric coatings optimize targeted release. Diverse end-user environments-from home care regimes to high-throughput outpatient clinics and hospital wards-demand bespoke packaging, dosing support and educational resources to enhance adherence.

The distribution network further delineates market access, as hospital pharmacies prioritize contract pricing and bulk procurement while online channels emphasize patient convenience and discreet shipping. Retail pharmacies bridge the gap between clinical prescription and consumer purchase, reinforcing brand recognition at the point of sale. Finally, the fundamental dichotomy between H2 receptor antagonists and proton pump inhibitors underpins product portfolios. H2 antagonists such as cimetidine, famotidine, nizatidine and ranitidine maintain a role in mild to moderate cases, whereas next-generation proton pump inhibitors including esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole lead innovation through superior acid suppression and improved safety profiles.

Deciphering Regional Variances in Peptic Ulcer Drug Consumption

Regional nuances profoundly influence both demand and product positioning across the Americas, Europe, Middle East & Africa and Asia-Pacific. In the Americas, established healthcare infrastructures and robust reimbursement frameworks favor the adoption of high-cost, high-efficacy therapies. Patient advocacy and direct‐to‐consumer education campaigns have elevated public awareness, strengthening the uptake of innovative proton pump inhibitors.

Across Europe, the Middle East and Africa, heterogeneous regulatory landscapes and varied payer models require tailored market entry strategies. Price controls and reference pricing in Europe contrast with emerging markets in North Africa and the Gulf, where private clinics often parallel public hospitals in driving product penetration. In Asia-Pacific, the rapid expansion of hospital networks and rising per capita healthcare spend combine with large patient populations to create compelling volume opportunities for both affordable generics and premium formulations. Local manufacturing partnerships and technology transfer agreements unlock cost efficiencies, enabling deeper market reach in diverse economic environments.

Spotlight on Leading Innovators and Market Forces

Leading pharmaceutical players are charting divergent paths to maintain competitive advantage. Multinational innovators are channeling investment into next-generation acid suppression mechanisms and fixed-dose combination therapies, reinforcing their patent portfolios through incremental innovation. Generics companies, on the other hand, focus on scaled production efficiencies and rapid market entry following patent expirations, leveraging established relationships with procurement agencies to maximize volume share.

Smaller biotech firms are exploring novel targets outside classical H2 and proton pump pathways, seeking to address residual unmet needs such as ulcer healing acceleration and mucosal protection. These emerging players often partner with contract research organizations to validate early-stage compounds and engage in licensing agreements with larger firms for late-stage development. Meanwhile, distribution specialists refine omnichannel logistics solutions to streamline product availability, integrating real-time tracking and digital prescription fulfillment to meet evolving patient expectations and regulatory requirements.

Strategic Imperatives to Navigate Future Market Challenges

To thrive in a rapidly shifting environment, industry leaders must adopt a multifaceted strategy. First, fostering collaborative partnerships with raw material suppliers and contract manufacturers will reduce exposure to tariff fluctuations and safeguard margins. Second, investing in patient-centric technology-such as digital adherence platforms and telehealth integrations-will enhance long-term treatment outcomes and differentiate offerings in a crowded marketplace.

Further, pursuing targeted acquisitions or licensing agreements can strengthen pipelines with complementary mechanisms, while divesting noncore assets liberates capital for high-yield R&D projects. Leadership teams should cultivate regulatory intelligence capabilities to anticipate policy changes, enabling proactive adjustments to clinical development programs and market access plans. Lastly, embedding sustainability criteria into manufacturing and distribution processes will not only meet emerging environmental standards but also resonate with corporate social responsibility commitments and payer expectations.

Rigorous Framework Underpinning Our Analytical Approach

Our analysis combines rigorous primary research with comprehensive secondary data review to ensure robust findings. Expert interviews with key opinion leaders in gastroenterology and pharmacology provided qualitative insights into evolving treatment paradigms and patient behaviors. These perspectives were augmented by detailed examination of regulatory filings, clinical trial registries and published literature, creating a solid evidentiary foundation for trend analysis.

We then cross-validated these inputs through market triangulation techniques, reconciling supply-side metrics such as production capacity and distribution volumes with demand-side indicators including prescription rates and reimbursement trajectories. Advanced segmentation modeling parsed performance across administration routes, sales channels, brand types, dosage forms, end users and drug classes, while regional mapping highlighted geographic disparities. Competitive benchmarking placed individual company initiatives within the broader industry context, ensuring that conclusions reflect both macro-level forces and micro-level strategic moves.

Synthesis of Insights and Implications for Stakeholders

This executive summary synthesizes the critical factors shaping the peptic ulcer drug market, from transformative segment dynamics and tariff impacts to differentiated regional behaviors and corporate strategies. Stakeholders now face a clear imperative to integrate these insights into cohesive action plans that balance innovation, affordability and operational resilience.

By understanding both the broad market shifts and the granular segmentation nuances, organizations can optimize their product portfolios, refine go-to-market strategies and bolster stakeholder engagement. The pathways illuminated here set the stage for sustainable growth, improved patient outcomes and strengthened competitive positioning in a field defined by rapid scientific progress and evolving healthcare frameworks.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Oral
    • Parenteral
  • Sales Channel
    • Over The Counter
    • Prescription Drugs
  • Brand Type
    • Branded
    • Generic
  • Dosage Form
    • Capsule
    • Injection
    • Tablet
  • End User
    • Home Care
    • Hospitals
    • Outpatient Clinics
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Drug Class
    • H2 Receptor Antagonists
      • Cimetidine
      • Famotidine
      • Nizatidine
      • Ranitidine
    • Proton Pump Inhibitors
      • Esomeprazole
      • Lansoprazole
      • Omeprazole
      • Pantoprazole
      • Rabeprazole
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AstraZeneca plc
  • Takeda Pharmaceutical Company Limited
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Bayer AG
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Peptic Ulcer Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Peptic Ulcer Drugs Market, by Sales Channel
9.1. Introduction
9.2. Over The Counter
9.3. Prescription Drugs
10. Peptic Ulcer Drugs Market, by Brand Type
10.1. Introduction
10.2. Branded
10.3. Generic
11. Peptic Ulcer Drugs Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.3. Injection
11.4. Tablet
12. Peptic Ulcer Drugs Market, by End User
12.1. Introduction
12.2. Home Care
12.3. Hospitals
12.4. Outpatient Clinics
13. Peptic Ulcer Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Peptic Ulcer Drugs Market, by Drug Class
14.1. Introduction
14.2. H2 Receptor Antagonists
14.2.1. Cimetidine
14.2.2. Famotidine
14.2.3. Nizatidine
14.2.4. Ranitidine
14.3. Proton Pump Inhibitors
14.3.1. Esomeprazole
14.3.2. Lansoprazole
14.3.3. Omeprazole
14.3.4. Pantoprazole
14.3.5. Rabeprazole
15. Americas Peptic Ulcer Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Peptic Ulcer Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Peptic Ulcer Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. AstraZeneca plc
18.3.2. Takeda Pharmaceutical Company Limited
18.3.3. Eisai Co., Ltd.
18.3.4. Pfizer Inc.
18.3.5. Johnson & Johnson
18.3.6. Sanofi S.A.
18.3.7. GlaxoSmithKline plc
18.3.8. Bayer AG
18.3.9. Novartis AG
18.3.10. Teva Pharmaceutical Industries Ltd
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. PEPTIC ULCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. PEPTIC ULCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. PEPTIC ULCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. PEPTIC ULCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. PEPTIC ULCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PEPTIC ULCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 65. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 69. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 74. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 119. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 120. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 128. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 129. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 133. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 146. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 147. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 151. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 152. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 155. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 156. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 160. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 191. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 192. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 196. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 206. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 209. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 210. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 213. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 214. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 218. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 219. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 242. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 245. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 246. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 250. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 254. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 255. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 259. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 272. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 273. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 276. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 278. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 281. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 282. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 285. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 286. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 306. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 309. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 310. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 313. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 314. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 315. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 316. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 318. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 319. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 322. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 323. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 324. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 327. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 328. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 331. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 332. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 339. AUSTRALIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILL

Companies Mentioned

The companies profiled in this Peptic Ulcer Drugs market report include:
  • AstraZeneca plc
  • Takeda Pharmaceutical Company Limited
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Bayer AG
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd

Methodology

Methodology DOWNLOAD NOW

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.99 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.43 Billion
Compound Annual Growth Rate5.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Peptic Ulcer Drugs Market by Product Type, Ulcer Type, Distribution Channel, and Region 2025-2033 - Product Image

Peptic Ulcer Drugs Market by Product Type, Ulcer Type, Distribution Channel, and Region 2025-2033

  • Report
  • 135 Pages
  • Global
From
EUR$2,999USDGBP
Peptic Ulcer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Peptic Ulcer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 215 Pages
  • Global
From
EUR$4,995USDGBP
Peptic Ulcer Drugs - Global Strategic Business Report - Product Image

Peptic Ulcer Drugs - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
EUR$5,850USDGBP
Anti-Peptic Ulcer Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Anti-Peptic Ulcer Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 90 Pages
  • Global
From
EUR$4,111USDGBP
Gastric Ulcers - Pipeline Insight, 2025 - Product Image

Gastric Ulcers - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
EUR$1,250USDGBP

About the Peptic Ulcer Drug Market

The Peptic Ulcer Drug market is a subset of the Gastrointestinal Drugs market, which includes medications used to treat diseases and disorders of the digestive system. Peptic Ulcer Drugs are used to treat peptic ulcers, which are sores that form in the lining of the stomach or small intestine. These drugs work by reducing the amount of acid produced in the stomach, which helps to reduce pain and promote healing. Commonly used Peptic Ulcer Drugs include proton pump inhibitors, H2 blockers, and antacids. The Peptic Ulcer Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, GlaxoSmithKline, AstraZeneca, Merck, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more